Clinical outcomes of and patient satisfaction with different incision methods for donor hepatectomy in living donor liver transplantation

Suk‐Won Suh, Kwang‐Woong Lee, Jeong‐Moo Lee, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh – 28 October 2014 – With the decrease in the average donor age and the increase in the proportion of female donors, both donor safety and cosmetic appearance are major concerns for some living donors in living donor liver transplantation (LDLT) because a large abdominal incision is needed that may influence the donor's quality of life. In all, 429 donors who underwent donor hepatectomy for LDLT from April 2010 to February 2013 were included in the study.

Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection

Georgios Grammatikos, Nerea Ferreiros, Dimitra Bon, Stephanie Schwalm, Julia Dietz, Caterina Berkowski, Daniel Fitting, Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Josef Pfeilschifter – 28 October 2014 – Ablation of very‐long‐chain ceramides (Cers) with consecutive elevations in sphinganine levels has been shown to cause a severe hepatopathy in a knockout mouse model. We have recently shown that serum sphingolipids (SLs) are deregulated in patients with chronic liver disease. However, their role as possible biomarkers in liver fibrosis remains to date unexplored.

Invasive aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases

Francesco Barchiesi, Susanna Mazzocato, Sara Mazzanti, Rosaria Gesuita, Edlira Skrami, Alessandro Fiorentini, Nina Singh – 28 October 2014 – Invasive aspergillosis (IA) in liver transplant recipients is associated with grave outcomes. We reviewed 116 individual cases reported in the literature from 1985 to 2013. IA was diagnosed after a median of 25 days after transplantation and involved a single organ in 51% of the cases, whereas in the remaining cases, multiple sites were involved.

Is Systemic heparinization necessary during living donor hepatectomy?

Joo Dong Kim, Dong Lak Choi, Young Seok Han – 28 October 2014 – Systemic heparinization has traditionally been performed during living donor hepatectomy (LDH) at most transplant centers because of the possibility of graft vascular thrombosis. However, no consensus on the use of systemic heparinization during LDH has yet emerged. The aims of the present study were to compare donor and recipient outcomes with reference to systemic heparinization and to determine whether or not systemic heparin needs to be administered to living donors.

The continuum of hepatitis C testing and care

Kendra Viner, Danica Kuncio, E. Claire Newbern, Caroline C. Johnson – 28 October 2014 – A hepatitis C virus (HCV)‐infected person will ideally have access to quality health care and move through the HCV continuum of care (CoC) from HCV antibody (Ab) screening, HCV‐RNA confirmation, engagement and retention in medical care, and treatment. Unfortunately, studies show that many patients do not progress through this continuum. Because these studies may not be generalizable, we assessed the HCV CoC in Philadelphia from January 2010 to December 2013 at the population level.

Subscribe to